Literature DB >> 11113751

Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making.

M G Oefelein1, A Feng, M J Scolieri, D Ricchiutti, M I Resnick.   

Abstract

OBJECTIVES: Based on methods introduced in the late 1960s and no longer used, serum testosterone level in men after surgical castration was reported to be 50 ng/dL or less. Radioimmunoassay and, subsequently, chemiluminescent methods have supplanted the early analytic methods because of their improved accuracy and ease of testing. The purpose of this study was to define the castrate testosterone level in the era of chemiluminescent testing.
METHODS: After bilateral orchiectomy, serum testosterone (total) levels were measured prospectively in 35 prostate cancer patients.
RESULTS: The median testosterone value in this patient cohort was 15 ng/dL (0.5 nmol/L; 95% confidence interval 12 to 17 ng/dL).
CONCLUSIONS: In a contemporary series, castrate testosterone should be defined as less than 20 ng/dL (0.7 nmol/L). The important biologic and economic implications are discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11113751     DOI: 10.1016/s0090-4295(00)00793-7

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  66 in total

1.  Comparison of serum testosterone levels in prostate cancer patients receiving LHRH agonist therapy with or without the removal of the prostate.

Authors:  Seetha Venkateswaran; David Margel; Stanley Yap; Karen Hersey; Paul Yip; Neil Eric Fleshner
Journal:  Can Urol Assoc J       Date:  2012-06       Impact factor: 1.862

2.  Goserelin versus leuprolide in the chemical castration of patients with prostate cancer.

Authors:  Élcio Dias Silva; Ubirajara Ferreira; Wagner Matheus; Eliney F Faria; Gustavo D Silva; Minori Saito; Auro A S de Souza; Azuil Laranjo; Otavio Clark; Luis Alberto Magna; Lísias Nogueira Castilho; Leonardo Oliveira Reis
Journal:  Int Urol Nephrol       Date:  2012-08       Impact factor: 2.370

3.  Individualized strategy for dosing luteinizing hormone-releasing hormone agonists for androgen-independent prostate cancer: identification of outcomes and costs.

Authors:  Jennifer A Wagmiller; Jennifer J Griggs; Andrew W Dick; Deepak M Sahasrabudhe
Journal:  J Oncol Pract       Date:  2006-03       Impact factor: 3.840

Review 4.  CYP17 inhibitors for prostate cancer therapy.

Authors:  Tadas S Vasaitis; Robert D Bruno; Vincent C O Njar
Journal:  J Steroid Biochem Mol Biol       Date:  2010-11-17       Impact factor: 4.292

Review 5.  Optimal pharmacotherapeutic management of hormone-sensitive metastatic prostate cancer.

Authors:  Ajjai Alva; Maha Hussain
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

Review 6.  Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer.

Authors:  Laurence Klotz; Rodney H Breau; Loretta L Collins; Martin E Gleave; Tom Pickles; Frederic Pouliot; Fred Saad
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

Review 7.  Treatment and prevention of bone complications from prostate cancer.

Authors:  Richard J Lee; Philip J Saylor; Matthew R Smith
Journal:  Bone       Date:  2010-05-31       Impact factor: 4.398

8.  Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients.

Authors:  Christopher M Pieczonka; Przemyslaw Twardowski; Joseph Renzulli; Jason Hafron; Deborah M Boldt-Houle; Stuart Atkinson; Scott Eggener
Journal:  Rev Urol       Date:  2018

9.  Clinical significance of suboptimal hormonal levels in men with prostate cancer treated with LHRH agonists.

Authors:  Jun Kawakami; Alvaro Morales
Journal:  Can Urol Assoc J       Date:  2013 Mar-Apr       Impact factor: 1.862

Review 10.  [Androgen deprivation for advanced prostate cancer].

Authors:  A Heidenreich; D Pfister; C H Ohlmann; U H Engelmann
Journal:  Urologe A       Date:  2008-03       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.